Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population
Downloads
Introduction: Lung cancer is a malignancy of the lung parenchyma or bronchi. Molecular targeted therapy directed at oncogene driver mutations, such as anaplastic lymphoma kinase (ALK), improves the prognosis of patients with non-small cell lung carcinoma (NSCLC). This study aimed to determine the characteristics of lung adenocarcinoma patients and the prevalence of ALK rearrangement among the North Sumatra population.
Methods: This descriptive study used data from patients' formalin-fixed paraffin-embedded (FFPE) ALK examination results and medical records. The laboratory analyzed the patient’s FFPE for ALK fusion protein expression using the VENTANA anti-ALK (D5F3) procedure to determine the prevalence of ALK rearrangement.
Results: Of the 34 subjects, it was revealed that the characteristics of lung adenocarcinoma patients were 18 patients aged >60 years old (52.9%), 26 male patients (76.4%), and 24 heavy smoker patients (70.6%). Based on the pathological tumor-node-metastasis (pTNM) stage, most samples were classified as stage IVA, with 24 cases (70.6%) showing the highest metastases to the pleura. There were 2 cases of ALK mutations obtained through immunohistochemical examination with a percentage of 5.8%.
Conclusion: There are relatively few ALK rearrangement mutations in lung adenocarcinoma patients without screening. Additional research is needed to ascertain the distribution of lung adenocarcinoma patient characteristics associated with a higher prevalence of ALK rearrangement mutations.
World Health Organization (WHO). Cancer. Geneva, https://www.who.int/health-topics/cancer#tab=tab_1 (2022).
Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. Treasure Island (FL), 2025. [PubMed]
Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev 2019; 28: 1563–1579. [PubMed]
Di Marco MV, Voena C. Review: Biological Implications of Oncogenic Rearrangements in Non-Small Cell Lung Cancer. Precis Cancer Med 2022; 5: 1–17. [Journal]
Syahruddin E, Wulandari L, Sri Muktiati N, et al. Uncommon EGFR Mutations in Cytological Specimens of 1,874 Newly Diagnosed Indonesian Lung Cancer Patients. Lung Cancer (Auckland, NZ) 2018; 9: 25–34. [Journal]
Chen MF, Chaft JE. Early-Stage Anaplastic Lymphoma Kinase (ALK)-Positive Lung Cancer: A Narrative Review. Transl Lung Cancer Res 2023; 12: 337–345. [PubMed]
Sinjab A, Rahal Z, Kadara H. Cell-by-Cell: Unlocking Lung Cancer Pathogenesis. Cancers (Basel); 14. Epub ahead of print July 2022. [PubMed]
Kozuma Y, Toyokawa G, Seto T. ALK Testing Methods: Is There a Winner or Loser? Expert Rev Anticancer Ther 2019; 19: 237–244. [Journal]
Zhao Z, Verma V, Zhang M. Anaplastic Lymphoma Kinase: Role in Cancer and Therapy Perspective. Cancer Biol Ther 2015; 16: 1691–1701. [PubMed]
Basit S, Ashraf Z, Lee K, et al. First Macrocyclic 3rd-Generation ALK Inhibitor for Treatment of ALK/ROS1 Cancer: Clinical and Designing Strategy Update of Lorlatinib. Eur J Med Chem 2017; 134: 348–356. [ScienceDirect]
Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. Clin Cancer Res 2008; 14: 4275–4283. [PubMed]
Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK Fusion Gene is Involved in Various Histologic Types of Lung Cancers from Nonsmokers with Wild-Type EGFR and KRAS. Cancer 2009; 115: 1723–1733. [PubMed]
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer who Harbor EML4-ALK. J Clin Oncol 2009; 27: 4247–4253. [PubMed]
Ren S, Chen X, Kuang P, et al. Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never-Smoker Women with Pulmonary Adenocarcinoma. Cancer 2012; 118: 5588–5594. [PubMed]
Heriyanto DS, Trisnawati I, Kumara EG, et al. The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. Pulm Med 2020; 2020: 3578748. [Journal]
Ahyati SN, Oktaviyanti IK, Yuliana I. Hubungan Jenis Kelamin dan Riwayat Merokok dengan Mutasi Gen EGFR pada Penderita Kanker Paru Tipe Adenokarsinoma. Homeostasis 2019; 2: 1–8. [Journal]
Fauziah K. Karakteristik Pasien Adenokarsinoma Paru Berdasarkan Faktor Risiko dan Derajat Histopatologi di Departemen Patologi Anatomi RSUP Dr. Hasan Sadikin Bandung Periode 2012-2017. Universitas Jenderal Achmad Yani, http://repository.unjani.ac.id/repository/efd4d797f937a28ae57ef656f8aab5ce.pdf (2019).
Purnamawati P, Tandrian C, Sumbayak EM, et al. Analisis Kejadian Kanker Paru Primer di Indonesia pada Tahun 2014-2019. J Kedokt Meditek 2021; 27: 164–172. [Journal]
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol 2022; 17: 362–387. [PubMed]
Soeroso NN, Ananda FR, Pradana A, et al. The Absence of Mutations in the Exon 2 KRAS Gene in Several Ethnic Groups in North Sumatra May Not the Main Factor for Lung Cancer. Acta Inform Med 2021; 29: 108–112. [PubMed]
Aktalina L. Hubungan Tingkatan Berat Merokok (Indeks Brinkman) dan Kejadian Kanker Paru. J Kedokt Methodist 2019; 12: 47–50. [Journal]
Arumsari D, Artanti KD, Martini S, et al. The Description of Smoking Degree based on Brinkman Index in Patients with Lung Cancer. J Berk Epidemiol 2019; 7: 249–256. [Journal]
Sánchez-Lara K, Turcott JG, Juárez E, et al. Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response with Quality of Life and Prognosis in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective Study. Nutr Cancer 2012; 64: 526–534. [PubMed]
Jusuf A, Wibawanto A, Icksan A, et al. Kanker Paru Jenis Karsinoma bukan Sel Kecil: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta, 2016.
Hofman P. Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives. Cancers; 16. Epub ahead of print 2024. [Journal]
Paolini D, Tiseo M, Demma F, et al. Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect. Clin Lung Cancer 2018; 19: e735–e743. [ScienceDirect]
Thorne-Nuzzo T, Williams C, Catallini A, et al. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol 2017; 12: 804–813. [ScienceDirect]
Doebele RC, Lu X, Sumey C, et al. Oncogene Status Predicts Patterns of Metastatic Spread in Treatment-Naive Nonsmall Cell Lung Cancer. Cancer 2012; 118: 4502–4511. [PubMed]
Copyright (c) 2025 Muhammad Yusuf Adira Putra, Noni Novisari Soeroso, Elisna Syahruddin, Evlina Suzanna, Dina Afiani, Taufik Ashar, Darren Wan-Teck Lim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (